

Magdalena Harris

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1781867/publications.pdf>

Version: 2024-02-01

76
papers

2,050
citations

236925

25
h-index

265206

42
g-index

79
all docs

79
docs citations

79
times ranked

2020
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors. <i>Harm Reduction Journal</i> , 2013, 10, 7.	3.2	206
2	Frequency of health care utilization by adults who use illicit drugs: a systematic review and meta-analysis. <i>Addiction</i> , 2020, 115, 1011-1023.	3.3	88
3	Methadone diversion as a protective strategy: The harm reduction potential of "generous constraints". <i>International Journal of Drug Policy</i> , 2013, 24, e43-e50.	3.3	81
4	Breaking worse: The emergence of krokodil and excessive injuries among people who inject drugs in Eurasia. <i>International Journal of Drug Policy</i> , 2013, 24, 265-274.	3.3	75
5	Injecting, Infection, Illness: Abjection and Hepatitis C Stigma. <i>Body and Society</i> , 2009, 15, 33-51.	0.7	70
6	Venous access and care: harnessing pragmatics in harm reduction for people who inject drugs. <i>Addiction</i> , 2012, 107, 1090-1096.	3.3	68
7	Taming systems to create enabling environments for HCV treatment: Negotiating trust in the drug and alcohol setting. <i>Social Science and Medicine</i> , 2013, 83, 19-26.	3.8	65
8	Fentanyl self-testing outside supervised injection settings to prevent opioid overdose: Do we know enough to promote it?. <i>International Journal of Drug Policy</i> , 2018, 58, 31-36.	3.3	58
9	Fire in the vein: Heroin acidity and its proximal effect on users' health. <i>International Journal of Drug Policy</i> , 2015, 26, 1103-1110.	3.3	57
10	Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. <i>International Journal of Drug Policy</i> , 2017, 47, 26-33.	3.3	53
11	Human rights and access to hepatitis C treatment for people who inject drugs. <i>International Journal of Drug Policy</i> , 2015, 26, 1072-1080.	3.3	52
12	Negotiating access to medical treatment and the making of patient citizenship: the case of hepatitis C treatment. <i>Sociology of Health and Illness</i> , 2013, 35, 1023-1044.	2.1	49
13	Opiate Injection-associated Skin, Soft Tissue, and Vascular Infections, England, UK, 1997-2016. <i>Emerging Infectious Diseases</i> , 2017, 23, 1400-1403.	4.3	48
14	Normalised pain and severe health care delay among people who inject drugs in London: Adapting cultural safety principles to promote care. <i>Social Science and Medicine</i> , 2020, 260, 113183.	3.8	48
15	Troubling biographical disruption: narratives of unconcern about hepatitis C diagnosis. <i>Sociology of Health and Illness</i> , 2009, 31, 1028-1042.	2.1	43
16	"Three in the Room". <i>Qualitative Health Research</i> , 2015, 25, 1689-1699.	2.1	42
17	Managing expense and expectation in a treatment revolution: Problematizing prioritisation through an exploration of hepatitis C treatment "benefit". <i>International Journal of Drug Policy</i> , 2017, 47, 161-168.	3.3	41
18	"I can't do this, it's too much": building social inclusion in cancer diagnosis and treatment experiences of Aboriginal people, their carers and health workers. <i>International Journal of Public Health</i> , 2014, 59, 373-379.	2.3	37

#	ARTICLE	IF	CITATIONS
19	Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom. <i>Journal of Viral Hepatitis</i> , 2016, 23, 479-486.	2.0	35
20	The Hepatitis C Awareness Through to Treatment (HepCATT) study: improving the cascade of care for hepatitis C virus-infected people who inject drugs in England. <i>Addiction</i> , 2019, 114, 1113-1122.	3.3	33
21	Health literacy in relation to cancer: addressing the silence about and absence of cancer discussion among Aboriginal people, communities and health services. <i>Health and Social Care in the Community</i> , 2013, 21, n/a-n/a.	1.6	31
22	â€œt's Russian rouletteâ€: Adulteration, adverse effects and drug use transitions during the 2010/2011 United Kingdom heroin shortage. <i>International Journal of Drug Policy</i> , 2015, 26, 51-58.	3.3	31
23	Injecting practices in sexual partnerships: Hepatitis C transmission potentials in a â€risk equivalenceâ€™ framework. <i>Drug and Alcohol Dependence</i> , 2013, 132, 617-623.	3.2	30
24	Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) â€“ a natural experiment (protocol). <i>BMJ Open</i> , 2019, 9, e029538.	1.9	30
25	Caring and curing: Considering the effects of hepatitis C pharmaceuticalisation in relation to non-clinical treatment outcomes. <i>International Journal of Drug Policy</i> , 2018, 60, 24-32.	3.3	28
26	Injecting-related health harms and overuse of acidifiers among people who inject heroin and crack cocaine in London: a mixed-methods study. <i>Harm Reduction Journal</i> , 2019, 16, 60.	3.2	28
27	The promise of treatment as prevention for hepatitis C: Meeting the needs of people who inject drugs?. <i>International Journal of Drug Policy</i> , 2015, 26, 963-969.	3.3	27
28	Tensions in relation: How peer support is experienced and received in a hepatitis C treatment intervention. <i>International Journal of Drug Policy</i> , 2017, 47, 221-229.	3.3	27
29	Prevalence and severity of abscesses and cellulitis, and their associations with other health outcomes, in a community-based study of people who inject drugs in London, UK. <i>PLoS ONE</i> , 2020, 15, e0235350.	2.5	27
30	An urgent impetus for action: safe inhalation interventions to reduce COVID-19 transmission and fatality risk among people who smoke crack cocaine in the United Kingdom. <i>International Journal of Drug Policy</i> , 2020, 83, 102829.	3.3	27
31	Navigating environmental constraints to injection preparation: the use of saliva and other alternatives to sterile water among unstably housed PWID in London. <i>Harm Reduction Journal</i> , 2020, 17, 24.	3.2	26
32	Staying Safe From Hepatitis C. <i>Qualitative Health Research</i> , 2012, 22, 31-42.	2.1	24
33	Understanding hepatitis C intervention successâ€”Qualitative findings from the Hep<sc>CATT</sc> study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 762-770.	2.0	23
34	Conceptualising hepatitis C stigma: A thematic synthesis of qualitative research. <i>International Journal of Drug Policy</i> , 2021, 96, 103320.	3.3	23
35	A qualitative assessment of the acceptability of hepatitis C remote self-testing and self-sampling amongst people who use drugs in London, UK. <i>BMC Infectious Diseases</i> , 2018, 18, 281.	2.9	22
36	One size fits all? The discursive framing of cultural difference in health professional accounts of providing cancer care to Aboriginal people. <i>Ethnicity and Health</i> , 2013, 18, 433-447.	2.5	21

#	ARTICLE	IF	CITATIONS
37	Restrictions on access to direct-acting antivirals for people who inject drugs: The European Hep-CORE study and the role of patient groups in monitoring national HCV responses. <i>International Journal of Drug Policy</i> , 2017, 47, 47-50.	3.3	21
38	The "do-it-yourself"™ New Zealand injecting scene: Implications for harm reduction. <i>International Journal of Drug Policy</i> , 2013, 24, 281-283.	3.3	20
39	"Care and Prevent"™: rationale for investigating skin and soft tissue infections and AA amyloidosis among people who inject drugs in London. <i>Harm Reduction Journal</i> , 2018, 15, 23.	3.2	20
40	More-than-harm reduction: Engaging with alternative ontologies of "movement"™ in UK drug services. <i>International Journal of Drug Policy</i> , 2020, 82, 102771.	3.3	20
41	A diagnosis of hepatitis C - insights from a study on patients' experiences. <i>Australian Family Physician</i> , 2010, 39, 589-92.	0.5	20
42	Incidence and treatment costs of severe bacterial infections among people who inject heroin: A cohort study in South London, England. <i>Drug and Alcohol Dependence</i> , 2020, 212, 108057.	3.2	19
43	Factors associated with skin and soft tissue infections among people who inject drugs in the United Kingdom: A comparative examination of data from two surveys. <i>Drug and Alcohol Dependence</i> , 2020, 213, 108080.	3.2	19
44	Injecting drug use, the skin and vasculature. <i>Addiction</i> , 2021, 116, 1914-1924.	3.3	19
45	Hep-CORE: a cross-sectional study of the viral hepatitis policy environment reported by patient groups in 25 European countries in 2016 and 2017. <i>Journal of the International AIDS Society</i> , 2018, 21, e25052.	3.0	17
46	Alcohol Related Hospital Admissions in a Country Town. <i>Australian Drug and Alcohol Review</i> , 1987, 6, 195-198.	0.1	14
47	Evidence-making controversies: the case of hepatitis C treatment and the promise of viral elimination. <i>Critical Public Health</i> , 2019, 29, 260-273.	2.4	14
48	The United Kingdom's first unsanctioned overdose prevention site; A proof-of-concept evaluation. <i>International Journal of Drug Policy</i> , 2022, 104, 103670.	3.3	14
49	Drawing attention to a neglected injecting-related harm: a systematic review of AA amyloidosis among people who inject drugs. <i>Addiction</i> , 2018, 113, 1790-1801.	3.3	13
50	"œt"™s Not Much of a Life"œ: The Benefits and Ethics of Using Life History Methods With People Who Inject Drugs in Qualitative Harm Reduction Research. <i>Qualitative Health Research</i> , 2018, 28, 1123-1134.	2.1	12
51	The Hep-CORE policy score: A European hepatitis C national policy implementation ranking based on patient organization data. <i>PLoS ONE</i> , 2020, 15, e0235715.	2.5	12
52	Social and structural determinants of injecting-related bacterial and fungal infections among people who inject drugs: protocol for a mixed studies systematic review. <i>BMJ Open</i> , 2021, 11, e049924.	1.9	12
53	Hepatitis C Avoidance in Injection Drug Users: A Typology of Possible Protective Practices. <i>PLoS ONE</i> , 2013, 8, e77038.	2.5	11
54	Hepatitis C testing for people who inject drugs in the United Kingdom: Why is uptake so low?. <i>Drugs: Education, Prevention and Policy</i> , 2014, 21, 333-342.	1.3	10

#	ARTICLE	IF	CITATIONS
55	Overdose prevention centres in the UK. <i>Lancet Public Health</i> , The, 2022, 7, e196-e197.	10.0	10
56	Ecologies of drug war and more-than-human health: The case of a chemical at war with a plant. <i>International Journal of Drug Policy</i> , 2021, 89, 103067.	3.3	9
57	Risk Environments and the Ethics of Reducing Drug-Related Harms. <i>American Journal of Bioethics</i> , 2017, 17, 46-48.	0.9	8
58	High prevalence of albuminuria amongst people who inject drugs: A cross-sectional study. <i>Scientific Reports</i> , 2020, 10, 7059.	3.3	7
59	Skin infections in Tanna, Vanuatu in 1989. <i>Papua and New Guinea Medical Journal</i> , 1992, 35, 137-43.	1.0	7
60	Enhanced primary care items. Their use in diabetes management. <i>Australian Family Physician</i> , 2001, 30, 1134-40.	0.5	7
61	Barriers to management of opioid withdrawal in hospitals in England: a document analysis of hospital policies on the management of substance dependence. <i>BMC Medicine</i> , 2022, 20, 151.	5.5	7
62	Pleasure and Guilt: Alcohol Use and Hepatitis C. <i>Qualitative Health Research</i> , 2010, 20, 1262-1271.	2.1	6
63	Roundtable discussion: how lessons learned from HIV can inform the global response to viral hepatitis. <i>BMC Infectious Diseases</i> , 2014, 14, S18.	2.9	5
64	The Berlin Hepatitis C Manifesto: access to prevention, testing, treatment and care for people who use drugs. <i>Hepatology, Medicine and Policy</i> , 2016, 1, 14.	1.7	5
65	Creativity, care and "messy" drug use: A collective history of the early days of peer-led needle exchange in Dunedin, New Zealand. <i>International Journal of Drug Policy</i> , 2021, 98, 103386.	3.3	5
66	Prevalence and factors associated with chronic venous insufficiency, leg ulceration and deep vein thrombosis among people who inject drugs in London, UK. <i>Drug and Alcohol Review</i> , 2022, 41, 677-685.	2.1	5
67	Relapse to Injecting Drug Use: A Hepatitis C Treatment Concern. <i>Contemporary Drug Problems</i> , 2009, 36, 303-326.	1.6	3
68	"Nothing about us, without us" Negotiating the personal and professional as activists and academics who use drugs. <i>International Journal of Drug Policy</i> , 2021, 98, 103533.	3.3	3
69	Commentary on Hancock et al. (2020): Low dead space syringes are just one component of an integrated package of care needed to tackle HCV and social exclusion among people who inject drugs. <i>Addiction</i> , 2020, 115, 714-715.	3.3	1
70	Patient monitoring of changes in the European policy response to viral hepatitis C treatment: Hep-CORE findings from 2016 to 2017. <i>Journal of Hepatology</i> , 2018, 68, S144-S145.	3.7	0
71	From stagnation to elimination: tracking hepatitis C elimination policy implementation in Europe in partnership with patient organizations. <i>Journal of Hepatology</i> , 2020, 73, S793-S794.	3.7	0
72	Childhood immunisation advisory service for general practitioners. <i>Australian Family Physician</i> , 1991, 20, 1495, 1497, 1501-2.	0.5	0

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 15, e0235715.		0
74	Title is missing!. , 2020, 15, e0235715.		0
75	Title is missing!.. , 2020, 15, e0235715.		0
76	Title is missing!.. , 2020, 15, e0235715.		0